| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
41,504,000 |
| Market
Cap: |
1.38(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$21.06 - $40.91 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 625 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
156,711 |
264,391 |
339,247 |
1,024,160 |
| Total Sell Value |
$5,273,227 |
$8,642,060 |
$10,368,131 |
$25,910,856 |
| Total People Sold |
3 |
5 |
6 |
7 |
| Total Sell Transactions |
4 |
11 |
14 |
43 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ciaffoni Joseph |
President and CEO |
• • – |
2019-05-31 |
4 |
D |
$11.51 |
$35,646 |
D/D |
(3,097) |
187,658 |
|
- |
|
| Ciaffoni Joseph |
President and CEO |
• • – |
2019-05-31 |
4 |
AS |
$11.52 |
$67,404 |
D/D |
(5,851) |
190,755 |
|
- |
|
| Heffernan Michael Thomas |
Director |
– • – |
2019-05-15 |
4 |
AS |
$12.74 |
$321,042 |
D/D |
(25,000) |
182,069 |
|
- |
|
| Heffernan Michael Thomas |
Director |
– • – |
2019-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,707 |
207,069 |
|
- |
|
| Melincoff Gwen A |
Director |
– • – |
2019-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,707 |
6,960 |
|
- |
|
| Freund John Gordon |
Director |
– • – |
2019-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,707 |
6,960 |
|
- |
|
| Hirsch David |
Director |
– • – |
2019-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,707 |
44,370 |
|
- |
|
| Bohlin Garen G |
Director |
– • – |
2019-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,707 |
6,960 |
|
- |
|
| Schroeder Theodore R |
Director |
– • – |
2019-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,707 |
6,960 |
|
- |
|
| Santini Gino |
Director |
– • – |
2019-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,707 |
30,148 |
|
- |
|
| Fallon John A. |
Director |
– • – |
2019-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,707 |
9,335 |
|
- |
|
| Heffernan Michael Thomas |
Director |
– • – |
2019-04-15 |
4 |
AS |
$14.91 |
$377,366 |
D/D |
(25,000) |
202,362 |
|
- |
|
| Malamut Richard |
EVP and Chief Medical Officer |
• – – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
42,500 |
|
- |
|
| Kuhlmann Shirley R. |
EVP and General Counsel |
• – – |
2019-03-15 |
4 |
D |
$16.98 |
$24,961 |
D/D |
(1,470) |
44,130 |
|
- |
|
| Heffernan Michael Thomas |
Director |
– • – |
2019-03-15 |
4 |
AS |
$17.17 |
$429,250 |
D/D |
(25,000) |
227,362 |
|
- |
|
| Heffernan Michael Thomas |
Director |
– • – |
2019-02-15 |
4 |
AS |
$14.71 |
$370,224 |
D/D |
(25,000) |
252,362 |
|
- |
|
| Brannelly Paul |
Executive Vice President & CFO |
• – – |
2019-02-08 |
4 |
D |
$14.39 |
$38,752 |
D/D |
(2,693) |
152,288 |
|
- |
|
| Ciaffoni Joseph |
President and CEO |
• • – |
2019-02-08 |
4 |
D |
$14.39 |
$29,528 |
D/D |
(2,052) |
196,606 |
|
- |
|
| Fleming Alison B |
Chief Technology Officer |
• – – |
2019-02-08 |
4 |
D |
$14.39 |
$39,054 |
D/D |
(2,714) |
75,254 |
|
- |
|
| Heffernan Michael Thomas |
Director |
– • – |
2019-02-08 |
4 |
D |
$14.39 |
$112,976 |
D/D |
(7,851) |
277,362 |
|
- |
|
| Brannelly Paul |
Executive Vice President & CFO |
• – – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
154,981 |
|
- |
|
| Dreyer Scott |
EVP & Chief Commercial Officer |
• – – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
25,600 |
41,786 |
|
- |
|
| Ciaffoni Joseph |
President and CEO |
• • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
198,658 |
|
- |
|
| Kuhlmann Shirley R. |
EVP and General Counsel |
• – – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
25,600 |
45,600 |
|
- |
|
| Fleming Alison B |
Chief Technology Officer |
• – – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
25,600 |
77,968 |
|
- |
|
406 Records found
|
|
Page 11 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.71 (2.19%) 
